Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Primate cell – per se
Reexamination Certificate
2011-07-26
2011-07-26
Lankford, Jr., Blaine (Department: 1651)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Primate cell, per se
C435S325000, C435S374000
Reexamination Certificate
active
07985586
ABSTRACT:
The present invention provides a cell culture enriched for sphingolipid enhances neural stem cells (SENSe), particularly oligodendrocyte precursor cells (ODPCs), that do not form teratomas after transplanted in vivo. Methods for producing and use of the invention ODPCs or the cell culture enriched with these ODPCs for stem cell therapy are also provided. The invention method comprises culturing a stem cell culture with a cell culture medium comprising a ceramide compound and a S1P receptor agonist in sequence, overlapping intervals or concurrent manners. The present invention further provides a cellular or gene therapy using a composition comprising a ceramide compound in conjunction with a S1P1agonist to proliferate or differentiate endogeneous neural stem cells to ODPCs and further to oligodendrocytes.
REFERENCES:
patent: WO00/09139 (2000-02-01), None
patent: WO2004/029203 (2004-04-01), None
patent: WO2007/056505 (2007-05-01), None
Yamada et al, 1996. Development and differentiation of oligodendrocytes. Japanese Journal of Physiology, vol. 46: 105-110.
Bieberich, 2004, “Integration of Glycosphingolipid Metabolism and Cell-Fate Decisions in Cancer and Stem Cells: Review and Hypothesis,” Glycoconjugate Journal, vol. 21(6):315-327.
Bieberich et al., 2004, “Selective Apoptosis of Pluripotent Mouse and Human Stem Cells by Novel Ceramide Analogues Prevents Teratoma Formation and Enriches for Neural Precursors in ES Cell-Derived Neural Transplants,” The Journal of Cell Biology, vol. 167(4):723-734.
Bieberich, 2008, “Smart Drugs for Smarter Stem Cells: Making SENSe (Sphingolipid-Enhanced Neural Stem Cells) of Ceramide,” Neuro-Signals, vol. 16(2-3):124-139.
Clemens et al., “Synthesis of 4(5)-Phenylimidazole-Based Analogues of Sphingosine-1-Phosphate and FTY720: Discovery of Potent S1P1 Receptor Agonists,” Bioorganic & Medicinal Chemistry Letters, vol. 15(15):3568-3572, 2005.
Dev et al., 2008, “Brain Sphingosine-1-Phosphate Receptors: Implication for FTY720 in the Treatment of Multiple Sclerosis,” Pharmacology & Therapeutics, vol. 117(1):77-93.
Jo et al., 2005, “S1P1-Selective in Vivo-Active Agonists from High-Throughput Screening: Off-the-Shelf Chemical Probes of Receptor Interactions, Signaling, and Fate,” Chemistry & Biology, vol. 12(6):703-715.
Miron et al., 2007, “FTY720 Modulates Human Oligodendrocyte Progenitor Process Extension and Survival,” Annals of Neurology, vol. 117(1):61-71.
Santos et al., 2004, “Synthesis and Biological Evaluation of Phosphonic and Thiophosphoric Acid Derivatives of Lysophosphatidic Acid,” Bioorganic & Medicinal Chemistry Letters, vol. 14(13):3473-3476.
Shimizu et al., 2005, “KRP-203, a Novel Synthetic Immunosuppressant, Prolongs Graft Survival and Attenuates Chronic Rejection in Rat Skin and Heart Allografts,” Circulation, vol. 111(2):222-229.
PCT International Search Report for PCT/US20091033056 dated Jul. 10, 2009 (8 pages).
Georgia Health Sciences University
Lankford, Jr. Blaine
Sutherland & Asbill & Brennan LLP
LandOfFree
Oligodendrocyte precursor cell composition and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligodendrocyte precursor cell composition and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligodendrocyte precursor cell composition and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2683689